Nova Zelândia - inglês - Medsafe (Medicines Safety Authority)

douglas pharmaceuticals limited - cyproterone acetate 50mg - tablet - 50 mg - active: cyproterone acetate 50mg excipient: lactose monohydrate magnesium stearate maize starch sodium starch glycolate starch

Nova Zelândia - inglês - Medsafe (Medicines Safety Authority)

orion pharma (nz) limited - carbidopa monohydrate 27mg equivalent to carbidopa 25 mg; entacapone 200mg; levodopa 100mg - film coated tablet - 100mg/25mg/200mg - active: carbidopa monohydrate 27mg equivalent to carbidopa 25 mg entacapone 200mg levodopa 100mg excipient: croscarmellose sodium ethanol glycerol hypromellose iron oxide red iron oxide yellow magnesium stearate maize starch mannitol polysorbate 80 povidone purified water sucrose titanium dioxide - the treatment of patients with parkinson's disease and end-of-dose motor fluctuations not stabilised on levodopa/dopa decarboxylase (ddc) inhibitor treatment.

Nova Zelândia - inglês - Medsafe (Medicines Safety Authority)

orion pharma (nz) limited - carbidopa monohydrate 33.8mg equivalent to 31.25 mg carbidopa; entacapone 200mg; levodopa 125mg - film coated tablet - 125mg/31.25mg/200mg - active: carbidopa monohydrate 33.8mg equivalent to 31.25 mg carbidopa entacapone 200mg levodopa 125mg excipient: croscarmellose sodium ethanol glycerol hypromellose iron oxide red magnesium stearate   maize starch mannitol polysorbate 80 povidone purified water sucrose titanium dioxide - stalevo is indicated for the treatment of patients with parkinson's disease and end-of-dose motor fluctuations not stabilised on levodopa/dopa decarboxylase (ddc) inhibitor treatment.

Nova Zelândia - inglês - Medsafe (Medicines Safety Authority)

orion pharma (nz) limited - carbidopa monohydrate 40.5mg equivalent to carbidopa 37.5 mg; entacapone 200mg; levodopa 150mg - film coated tablet - 150mg/37.5mg/200mg - active: carbidopa monohydrate 40.5mg equivalent to carbidopa 37.5 mg entacapone 200mg levodopa 150mg excipient: croscarmellose sodium ethanol glycerol hypromellose iron oxide red iron oxide yellow magnesium stearate maize starch mannitol polysorbate 80 povidone purified water sucrose titanium dioxide - the treatment of patients with parkinson's disease and end-of-dose motor fluctuations not stabilised on levodopa/dopa decarboxylase (ddc) inhibitor treatment.

Nova Zelândia - inglês - Medsafe (Medicines Safety Authority)

orion pharma (nz) limited - carbidopa monohydrate 54.1mg equivalent to 50 mg carbidopa; entacapone 200mg; levodopa 200mg - film coated tablet - 200mg/50mg/200mg - active: carbidopa monohydrate 54.1mg equivalent to 50 mg carbidopa entacapone 200mg levodopa 200mg excipient: croscarmellose sodium ethanol glycerol hypromellose iron oxide red magnesium stearate   maize starch mannitol polysorbate 80 povidone purified water   sucrose titanium dioxide - latest regulatory activity

Nova Zelândia - inglês - Medsafe (Medicines Safety Authority)

orion pharma (nz) limited - carbidopa monohydrate 13.5mg equivalent to carbidopa 12.5 mg; entacapone 200mg; levodopa 50mg - film coated tablet - 50mg/12.5mg/200mg - active: carbidopa monohydrate 13.5mg equivalent to carbidopa 12.5 mg entacapone 200mg levodopa 50mg excipient: croscarmellose sodium ethanol glycerol hypromellose iron oxide red iron oxide yellow magnesium stearate maize starch mannitol polysorbate 80 povidone purified water sucrose titanium dioxide - the treatment of patients with parkinson's disease and end-of-dose motor fluctuations not stabilised on levodopa/dopa decarboxylase (ddc) inhibitor treatment.

Nova Zelândia - inglês - Medsafe (Medicines Safety Authority)

orion pharma (nz) limited - carbidopa monohydrate 20.25mg equivalent to 18.75 mg carbidopa; entacapone 200mg; levodopa 75mg - film coated tablet - 75mg/18.75mg/200mg - active: carbidopa monohydrate 20.25mg equivalent to 18.75 mg carbidopa entacapone 200mg levodopa 75mg excipient: croscarmellose sodium ethanol glycerol hypromellose iron oxide red magnesium stearate   maize starch mannitol polysorbate 80 povidone purified water sucrose titanium dioxide - stalevo is indicated for the treatment of patients with parkinson's disease and end-of-dose motor fluctuations not stabilised on levodopa/dopa decarboxylase (ddc) inhibitor treatment.

Nova Zelândia - inglês - Medsafe (Medicines Safety Authority)

sandoz new zealand limited - allopurinol 100mg;   - tablet - 100 mg - active: allopurinol 100mg   excipient: crospovidone macrogol 4000 magnesium stearate microcrystalline cellulose povidone powdered cellulose purified talc

Nova Zelândia - inglês - Medsafe (Medicines Safety Authority)

sandoz new zealand limited - allopurinol 300mg;   - tablet - 300 mg - active: allopurinol 300mg   excipient: crospovidone macrogol 4000 magnesium stearate microcrystalline cellulose povidone powdered cellulose purified talc

Reino Unido - inglês - MHRA (Medicines & Healthcare Products Regulatory Agency)

genus pharmaceuticals ltd - lisinopril; hydrochlorothiazide - oral tablet - 10mg ; 12.5mg